Study for CF treatments for people without modulators
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have a confirmed diagnosis of cystic fibrosis (CF) — by a sweat test or genetic testing.
- You are not eligible for CFTR modulators (like Kalydeco, Orkambi, Trikafta) or you haven't taken one for at least 28 days and won't start or restart during the study.
- Your health has been stable (no major changes) for the past 28 days.
- You have not had a lung transplant.
- You are not pregnant or planning to get pregnant (if you are of childbearing age).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests an individualized approach (“theratyping”) to match your cystic fibrosis (CF) to the CFTR medicine that may work best for your specific genetic change. It may help find a more tailored treatment plan and see how your body responds, while using medicines that are already approved for some people with CF.
This study collects cells from people with cystic fibrosis (CF) caused by rare CFTR gene changes. The goal is to build a cell bank for future research, which may help scientists develop better tests and treatments for rare CF types.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.